NIH chief says comparative studies hold risk for personalized medicine
The use of comparative-effectiveness research as a means to reduce health care costs could jeopardize the advances in personalized medicine because such studies tend to miss groups of people who might benefit from a particular treatment, NIH Director Dr. Francis Collins said. "We need to be mindful of the goal of comparative-effectiveness research and not lose all that we have gained in understanding how individuals differ and how that could be factored into better diagnostics and preventive strategies," Collins said.
Reuters | 10/27
This story published in BIO SmartBrief on 10/27/2009
NIH chief names members of stem cell-line work group
Tuesday, September 22, 2009
Obama nominates geneticist Collins as NIH chief
Thursday, July 9, 2009
Deal-making, collaboration on the rise in drug-development sector
Monday, November 23, 2009
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|